Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 272,812 shares, a decline of 53.3% from the August 15th total of 584,609 shares. Based on an average daily trading volume, of 1,219,586 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

CELZ has been the topic of several research reports. Weiss Ratings upgraded shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Finally, Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology presently has a consensus rating of “Hold”.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Stock Performance

Shares of NASDAQ CELZ opened at $0.96 on Monday. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $1.68. Creative Medical Technology has a fifty-two week low of $0.62 and a fifty-two week high of $6.25. The stock has a market cap of $6.33 million, a PE ratio of -0.46 and a beta of 2.04.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, sell-side analysts predict that Creative Medical Technology will post -1.18 EPS for the current year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.